Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Abbott Laboratories ... had cleared the Libre Rio, a new over-the-counter (OTC) CGM option for type 2 diabetes patients who do not use insulin (the FreeStyle Libre targets insulin and non-insulin ...

Thursday, Abbott Laboratories ... Glucose Monitoring To Type 2 Diabetes Patients. This recall involves removing certain devices from where they are used or sold and does not apply to the FreeStyle ...

Abbott announced ... To Type 2 Diabetes Patients. This recall involves removing certain devices from where they are used or sold and does not apply to the FreeStyle Libre 3 reader or app.

Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...

Abbott launched an over-the-counter continuous glucose monitoring system, Lingo, for adults not on insulin -- the second such ...

Abbott’s FreeStyle Libre products have more than six million users who have type 1 or type 2 diabetes. She added that the collaboration provides people with diabetes expanded choice, calling it ...

It’s aimed at the 25 million people with Type 2 diabetes and those with prediabetes ... of Nutrisense and Levels – which use Abbott FreeStyle Libre CGMs and can cost in excess of $250 a ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...